As of November 15th, Rodrigo Leite de Oliveira (PharmD, PhD) will start as the new Cancer Center Amsterdam and Amsterdam UMC CRISPR Platform manager (www.crispr-platform.nl). Rodrigo is a former EMBO fellow who has been working on functional cancer genomics with René Bernards (NKI-AvL). Rodrigo will be supporting different CRISPR projects, such as improving precise gene editing techniques and designing dedicated human and mouse CRISPR gRNA libaries for rapid screens. As soon as the corona situation permits, you will find Rodrigo either at location AMC (Louis Vermeulen lab) or location VUmc (Oncogenetics, Rob Wolthuis lab). Rodrigo’s appointment is co-financed by the CCA and the Amsterdam UMC Innovation Fund. Questions for CRISPR platform support can be directed at firstname.lastname@example.org.
The CRISPR technique enables us to make precise changes to the DNA. For example, treatment-resistant cancer cells can be made susceptible to immunotherapy. In order to take full advantage of possible applications of this new technique, we have recruited an expert in the field of CRISPR. With the launch of an online platform with current relevant information involving CRISPR, professionals can ask questions and get help setting up studies. This has already proven successful: several grants utilizing the CRISPR technology have recently been awarded. In addition, courses and seminars have been developed to provide information and education about CRISPR applications.